Advertisement

Conus striatus venom exhibits non-hepatotoxic and non-nephrotoxic potent analgesic activity in mice

  • Rofel Vincent S. Jagonia
  • Rejemae G. Dela Victoria
  • Lydia M. Bajo
  • Roger S. TanEmail author
Rapid Communication
  • 14 Downloads

Abstract

Constant research into the pharmaceutical properties of marine natural products has led to the discovery of many potentially active agents considered worthy of medical applications. Genus Conus, which approximately comprises 700 species, is currently under every researcher’s interest because of the conopeptides in their crude venom. Conopeptides have a wide range of pharmacological classes and properties. This research focused on the crude venom of Conus striatus to assess its analgesic activity, mutagenicity, nephrotoxicity, and hepatotoxicity in mice. The crude venom was extracted from the conus snails and the protein concentration was determined using Bradford’s method. The analgesic activity of the venom was determined using the hot-plate method and standard IFCC method was used to determine the alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Evaluation of mutagenicity was done using micronucleus assay and the nephrotoxicity of the venom was determined using Kidney Coefficient and serum creatinine concentration. The maximum tolerable dose (MTD) of the crude venom was found to be 75 ppm. The venom exhibited potent analgesic activity even higher than the positive control (Ibuprofen). Most of the analgesic drugs can usually impact damage in the liver and kidneys. However, AST and ALT results revealed that the venom has no adverse effects on the liver. Although the venom increased the incidence of micronucleated polychromatic erythrocytes, making it mutagenic, with MTD concentration’s mutagenicity comparable to the positive control methyl methanesulfonate (MMS). The kidney coefficients, on the other hand, showed no significant difference between the treated groups and that of the untreated group. The serum creatinine also showed a concentration-dependent increase; with MTD treated mice got the highest creatinine concentration. However, MTD/2 and MTD/4 showed no significant difference in creatinine levels with respect to the untreated groups. Hence, the nephrotoxicity of the venom was only evident when used at higher concentration. The venom exhibited potent analgesic activity indicated that the C. striatus crude venom extract could have a potential therapeutic component as analgesic drugs that displayed no hepatic damage. This study also suggests that for this venom to be utilized for future medical applications, their usage must be regulated and properly monitored to avoid nephrotoxic effect.

Keywords

Conus striatus Mutagenicity Nephrotoxicity Hepatotoxicity Analgesic AST ALT 

Notes

Acknowledgements

RVSJ and RGDV contributed equally to this research. The authors would like to acknowledge Enjelyn C. Gomez of the MSU-IIT Chemistry Department for the assistance in performing the assays and to the Chemistry Department of De La Salle University.

Compliance with ethical standards

Conflict of interest

The authors declared no conflict of interest.

References

  1. 1.
    Prashanth JR, Dutertre S, Lewis RJ (2017) Pharmacology of predatory and defensive venom peptides in cone snails. Mol BioSyst 13(12):2453–2465Google Scholar
  2. 2.
    PuillandreN Duda TF, Meyer C, Olivera BM, Bouchet P (2015) One, four or 100 genera? A new classification of the cone snails. J Mollus Stud 81:1–23Google Scholar
  3. 3.
    Conticello S, Gilad Y, Avidan N, Ben-Asher E, Levy Z, Fainzilber M (2001) Mechanisms for evolving hypervisibility: the case of conopeptides. Mol Biol Evol 18(2):120–131Google Scholar
  4. 4.
    Lavergne V, Harliwong I, Jones A, Miller D, Taft RJ, Alewood PF (2015) Optimized deep targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks. Proc Natl Acad Sci 112:E3782–E3791Google Scholar
  5. 5.
    Duda TF Jr, Kohn AJ (2005) Species-level phylogeography and evolutionary history of the hyperdiverse marine gastropod genus Conus. Mol Phylogenet Evol 34(2):257–272Google Scholar
  6. 6.
    Buczek O, Bulaj G, Olivera B (2005) Conotoxins and posttranslational modification of secreted gene products. Cell Mol Life Sci 62(24):3067–3079Google Scholar
  7. 7.
    Pi C, Liu Y, Peng C, Jiang X, Liu J, Xu B, Yu X, Yu Y, Jiang X, Wang L, Dong M, Chen S, Xu AL (2006) Analysis of expressed sequence tags from the venom ducts of Conus striatus: focusing on the expression profile of conotoxins. Biochime 88(2):131–140Google Scholar
  8. 8.
    Olivera BM, Safavi-henami H, Horvath MP, Teichert RW (2016) Conopeptides, marine natural products from venoms: biomedical applications and future research applications. In: Baker BJ (ed) Marine biomedicine: from beach to bedside. CRC Press, Boca Raton, pp 463–496Google Scholar
  9. 9.
    Lewis RJ, Garcia ML (2003) Therapeutic potential of venom peptides. Nat Rev Drug Discov 2:790–802Google Scholar
  10. 10.
    Lewis RJ, Dutertre S, Vetter I, Christie MJ (2012) Conus venom peptide pharmacology. Pharmacol Rev 64:259–298Google Scholar
  11. 11.
    Cruz IJ, White J (1955) Clinical toxicology of conus snail stings. In: Meier J, White J (eds) Clinical toxicology of animal venoms. CRC Press, Boca RatonGoogle Scholar
  12. 12.
    Green B, Olivera B (2016) Venom peptides from cone snails. Na channels from phyla to function. Curr Top Membr 78:65–86Google Scholar
  13. 13.
    Jimenez EC, Cruz LJ (2017) Conotoxins as tools in research on nicotinic receptors. Toxins Drug Discov 1:189–204Google Scholar
  14. 14.
    Nelson L (2004) News feature: one slip, and you’re dead. Nature 429:798–799Google Scholar
  15. 15.
    Tabaraki N, Shahbazzadeh D, Moradi MA, Vosughi G, Mostafavi PG (2014) Analgesic effect of Persian Gulf Conus textile venom. Iran J Basic Med Sci 17:793–797Google Scholar
  16. 16.
    Eisapoor SS, Jamili S, Shahbazzadeh D, Mostafavi PG, Bagheri KP (2016) A new, high yield, rapid, and cost-effective protocol to deprotection of cysteine-rich conopeptide, omega-conotoxin MVIIA. Chem Biol Drug Des 87:687–693Google Scholar
  17. 17.
    Zafaralla GC, Ramilo C, Gray WR, Karlstrom R, Olivera BM, Cruz LJ (1998) Phylogenetic specificity of cholinergic ligands: alpha.-conotoxin SI. Biochemistry 27:7102–7105Google Scholar
  18. 18.
    Myers RA, Zafaralla GC, Gray WR, Abbott J, Cruz LJ, Olivera BM (1991) Alpha-conotoxins, small peptide probes of nicotinic acetylcholine receptors. Biochemistry 30:9370–9377Google Scholar
  19. 19.
    Bajo LM, Tan RS, Lagas KFM, Perocho RCJB, Gomez EC (2017) Biological characterization of Conus striatus venom for medical applications. Sci Int 29(6):1277–1281Google Scholar
  20. 20.
    Saravanan R et al (2009) Isolation, purification and biochemical characterization of conotoxin from Conus figulinus Linnaeus (1758). SRM University, ChennaiGoogle Scholar
  21. 21.
    Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254Google Scholar
  22. 22.
    Hayashi M, Morita T, Kodama Y, Sofuni T, Ishidate M Jr (1990) The micronucleus assay with mouse peripheral blood erythrocytes using acridine orange-coated slides. Mutat Res Lett 245(4):245–249Google Scholar
  23. 23.
    Schumann G, Bonora R, Ceriotti F et al (2002) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med 40:725–733Google Scholar
  24. 24.
    Schumann G, Bonora R, Ceriotti F et al (2002) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 40:718–724Google Scholar
  25. 25.
    Hørder M, Elser RC, Gerhardt W et al (1990) International Federation of Clinical Chemistry (IFCC): Scientific Division, Committee on Enzymes. IFCC methods for the measurement of catalytic concentration of enzymes. Part 7. IFCC method for creatine kinase (ATP: creatine (N-phosphotransferase, EC 2.7.3.2). IFCC Recommendation. J Autom Chem 12(1):22–40Google Scholar
  26. 26.
    Eddy NB, Leimbach D (1953) Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 107(3):385–393Google Scholar
  27. 27.
    Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16(2):109–110Google Scholar
  28. 28.
    D’Amour FE, Smith DL (1941) A method of determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79Google Scholar
  29. 29.
    Brooks PM, Day RO (1991) Nonsteroidal anti-inflammatory drugs-differences and similarities. N Engl J Med 324:1716–1725Google Scholar
  30. 30.
    Zhang G, Xia Y-J, Guo X-X, Zhu B-L, Zhang G-M, Ma X-B, Yu H, Wang H-J, Wang G-S, Yang L, Zhou Y-T (2014) Reference intervals of total bilirubin, ALT, AST, and creatinine in healthy elderly Chinese. Med Sci Monit 20:1778–1782.  https://doi.org/10.12659/msm.892148 Google Scholar
  31. 31.
    Tan RS and Bajo LM (2014) Modulation of Tinosporarumphii and zinc salt on DNA damage in quinoline-induced genotoxicity and hepatotoxicity in male albino mice. Advances in Toxicology. Article ID 201762.  https://doi.org/10.1155/2014/201762
  32. 32.
    Pelz-Sinvani N, Klempfner R, Ramaty E, SelaBA Goldenberg I, Segal G (2016) Low ALT levels independently associated with 22-year all-cause mortality among coronary heart disease patients. J Gen Intern Med 31(2):209–214.  https://doi.org/10.1007/s11606-015-3480-6 Google Scholar
  33. 33.
    Botros M, Sikaris K (2013) The De Ritis ratio: the test of time. Clin Biochem Rev 34(3):117–130Google Scholar
  34. 34.
    Cohen JA, Kaplan MM (1979) The SGOT/SGPT ratio, an indicator of alcoholic liver disease. Digest Dis 24:835–838Google Scholar
  35. 35.
    Gault MH, Barrett BJ (1998) Analgesic nephropathy. Am J Kidney Dis 32(3):351–360Google Scholar
  36. 36.
    Yaxley J (2016) Common analgesic agents and their roles in analgesic nephropathy: a commentary on the evidence Korean. J Fam Med 37(6):310–316Google Scholar
  37. 37.
    Van Veldhuisen DJ, Ruilope LM, Maisel AS, Damman K (2016) Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. Eur Heart J 37:2577–2585Google Scholar
  38. 38.
    Chiou WL, Hsu FH (1975) Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharmacol 15(5–6):427–434Google Scholar
  39. 39.
    Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483Google Scholar
  40. 40.
    Mizuno M, Ito Y, Paul Morgan B (2012) Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Mar Drugs 10:1582–1604Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Chemistry, College of Science and MathematicsMindanao State University-Iligan Institute of TechnologyTibanga Iligan CityPhilippines
  2. 2.Department of Chemistry, College of ScienceDe La Salle UniversityManilaPhilippines

Personalised recommendations